MGTX Overview

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.

Wall Street analysts forecast MGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGTX is21.50 USD with a low forecast of 14.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

MeiraGTx Holdings PLC revenue for the last quarter amounts to 75.36M USD, increased 252.33

MeiraGTx Holdings PLC. EPS for the last quarter amounts to 0.19 USD, decreased -138.00

MeiraGTx Holdings PLC (MGTX) has 400 emplpoyees as of April 17 2026.

Today MGTX has the market capitalization of 916.27M USD.